KLK3 and prostate carcinoma: Although the methodology described in this study is not suitable for the routine clinical diagnosis of prostate cancer, the identification of these PSA glycoforms in aggressive PCa patients paves the way to improve the diagnosis of aggressive PCa by designing methodologies addressed to specifically measure those PSA glycoforms, such as imprinted nanoparticles or biosensors57,58.